Sage Rhino Capital’s Cytokinetics CYTK Stock Holding History

Sage Rhino Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,439	Closed	-$204K	–	241
2023 Q4	$204K	Buy	+2,439	New	+$88.3K	0.05%	203

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sage Rhino Capital's CYTK Position: Q1 2024 in Review

Sage Rhino Capital sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 2,439 shares — an estimated $204K sold.

Sage Rhino Capital first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $204K in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Sage Rhino Capital reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
Sage Rhino Capital sold 2,439 Cytokinetics shares in Q1 2024, an estimated $204K.
Sage Rhino Capital first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
Sage Rhino Capital's Cytokinetics position peaked at $204K in Q4 2023.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Sage Rhino Capital's 13F filing for Q1 2024, filed 26 Apr 2024.